Listed

Zevra Therapeutics, Inc.

ZVRANasdaqCIK 1434647HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$39.7mRevenue, Q2 FY2026, three months to 2026-06-30$39.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$39.7mRevenue, Q2 FY2026, three months to 2026-06-30$39.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure+53.3% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin42.3%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $16.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Revenue: $39.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure+316.8 pts on a year earlier
  • Net margin22.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $8.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Revenue: $39.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure−266.6 pts on a year earlier
  • Diluted EPS$0.14Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure−88.4% on a year earlier
  • Free cash flow$16.8mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $17.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001434647-26-000068. Derived: 6-month figure less the 3-month figure.Capital expenditure: $217.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001434647-26-000068. Derived: 6-month figure less the 3-month figure.Report this figureSign changed from a year earlier

Last eight quarters

Full statements
Revenue$39.7mOperating margin 42.3%
Diluted EPS$0.14, Q2 FY2026
Free cash flow$16.8m, Q2 FY2026
Zevra Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m3.7Revenue, Q3 FY2024, three months to 2024-09-30$3.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Report this figure12.0Revenue, Q4 FY2024, three months to 2024-12-31$12.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure20.4Revenue, Q1 FY2025, three months to 2025-03-31$20.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Report this figure25.9Revenue, Q2 FY2025, three months to 2025-06-30$25.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure26.1Revenue, Q3 FY2025, three months to 2025-09-30$26.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Report this figure34.1Revenue, Q4 FY2025, three months to 2025-12-31$34.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure36.2Revenue, Q1 FY2026, three months to 2026-03-31$36.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Report this figure39.7Revenue, Q2 FY2026, three months to 2026-06-30$39.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(739.0%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$27.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Revenue: $3.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Report this figure(128.0%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$15.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $12.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(26.3%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$5.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Revenue: $20.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Report this figure(274.5%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$71.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Revenue: $25.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure15.9%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Revenue: $26.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Report this figure27.3%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $9.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $34.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure144.0%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $52.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Revenue: $36.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Report this figure42.3%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $16.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Revenue: $39.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure
Net margin%(899.2%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$33.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Revenue: $3.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Report this figure(296.8%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$35.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $12.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(15.2%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$3.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Revenue: $20.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Report this figure288.7%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $74.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Revenue: $25.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure(2.1%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$544.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Revenue: $26.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Report this figure35.6%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $12.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Revenue: $34.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure104.6%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $37.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Revenue: $36.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Report this figure22.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $8.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Revenue: $39.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure
Diluted EPS$ per share(0.69)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Report this figurenot reported (Diluted EPS not reported)(0.06)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Report this figure1.21Diluted EPS, Q2 FY2025, three months to 2025-06-30$1.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure(0.01)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001434647-25-000011.Report this figurenot reported (Diluted EPS not reported)0.60Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Report this figure0.14Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001434647-26-000068.Report this figure
Free cash flow$m(18.1)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$18.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001434647-25-000011. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001434647-25-000011. Derived: 9-month figure less the 6-month figure.Report this figure(16.3)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$16.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(8.3)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$8.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Capital expenditure: $99.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Report this figure(3.8)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001434647-26-000068. Derived: 6-month figure less the 3-month figure.Capital expenditure: $213.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001434647-26-000068. Derived: 6-month figure less the 3-month figure.Report this figure4.2Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $4.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001434647-25-000011. Derived: 9-month figure less the 6-month figure.Capital expenditure: $554.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001434647-25-000011. Derived: 9-month figure less the 6-month figure.Report this figure5.5Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Capital expenditure: −$31.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-09, accession 0001434647-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure6.1Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $6.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Capital expenditure: $35.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001434647-26-000031.Report this figure16.8Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $17.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001434647-26-000068. Derived: 6-month figure less the 3-month figure.Capital expenditure: $217.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001434647-26-000068. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$106.5mOperating margin −59.1%
Diluted EPS$1.35, FY2025
Free cash flow−$2.4m, FY2025
Zevra Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m28.7Revenue, FY2021, twelve months to 2021-12-31$28.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2023-03-07, accession 0001437749-23-005703.Report this figure10.2Revenue, FY2022, twelve months to 2022-12-31$10.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-04-01, accession 0001437749-24-010430.Report this figure27.5Revenue, FY2023, twelve months to 2023-12-31$27.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-12, accession 0001437749-25-007320.Report this figure23.6Revenue, FY2024, twelve months to 2024-12-31$23.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011.Report this figure106Revenue, FY2025, twelve months to 2025-12-31$106.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%27.0%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $7.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-07, accession 0001437749-23-005703.Revenue: $28.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2023-03-07, accession 0001437749-23-005703.Report this figure(418.9%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$42.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-04-01, accession 0001437749-24-010430.Revenue: $10.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-04-01, accession 0001437749-24-010430.Report this figure(180.6%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$49.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-12, accession 0001437749-25-007320.Revenue: $27.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-12, accession 0001437749-25-007320.Report this figure(368.5%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$87.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001434647-26-000011.Revenue: $23.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011.Report this figure(59.1%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$62.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001434647-26-000011.Revenue: $106.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011.Report this figure
Net margin%(29.9%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$8.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-07, accession 0001437749-23-005703.Revenue: $28.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2023-03-07, accession 0001437749-23-005703.Report this figure(263.5%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$26.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-04-01, accession 0001437749-24-010430.Revenue: $10.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-04-01, accession 0001437749-24-010430.Report this figure(167.7%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$46.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-12, accession 0001437749-25-007320.Revenue: $27.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-12, accession 0001437749-25-007320.Report this figure(446.9%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$105.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001434647-26-000011.Revenue: $23.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011.Report this figure78.2%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $83.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001434647-26-000011.Revenue: $106.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-09, accession 0001434647-26-000011.Report this figure
Diluted EPS$ per share(2.11)Diluted EPS, FY2021, twelve months to 2021-12-31−$2.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2022-03-31, accession 0001437749-22-007725.Report this figurenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)(2.28)Diluted EPS, FY2024, twelve months to 2024-12-31−$2.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-09, accession 0001434647-26-000011.Report this figure1.35Diluted EPS, FY2025, twelve months to 2025-12-31$1.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-09, accession 0001434647-26-000011.Report this figure
Free cash flow$m10.3Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $10.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-07, accession 0001437749-23-005703.Capital expenditure: $102.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-07, accession 0001437749-23-005703.Report this figure(18.8)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$18.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-04-01, accession 0001437749-24-010430.Capital expenditure: $93.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-04-01, accession 0001437749-24-010430.Report this figure(33.8)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$33.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-12, accession 0001437749-25-007320.Capital expenditure: $296.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-12, accession 0001437749-25-007320.Report this figure(69.7)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$69.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001434647-26-000011.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-09, accession 0001434647-26-000011.Report this figure(2.4)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001434647-26-000011.Capital expenditure: $835.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-09, accession 0001434647-26-000011.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Zevra Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$73.3m5,108,871Added+652,395
FMR LLC2026-06-30$70.5m4,915,717Added+1,703,840
Woodline Partners LP2026-06-30$68.6m4,785,771Added+1,334,828
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$37.8m2,638,910Added+169,582
Caption Management, LLC2026-06-30$28.7m2,002,800PutUnchanged
Nantahala Capital Management, LLC2026-06-30$25.8m1,797,476Reduced−724,460
Nantahala Capital Management, LLC2026-06-30$25.8m1,797,476Reduced−724,460
STATE STREET CORP2026-06-30$24.1m1,681,999Added+120,430
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$22.1m1,540,936Added+169,079
D. E. Shaw & Co., Inc.2026-06-30$18.7m1,306,949Added+460,492

Recent filings

All 865 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Zevra Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0521:19 ET10-QQuarterly reportPeriod 2026-06-300001434647-26-000068
2026-08-0520:13 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001434647-26-000067
2026-06-0520:19 ET8-K5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001434647-26-000041
2026-05-0621:14 ET10-QQuarterly reportPeriod 2026-03-310001434647-26-000031
2026-05-0620:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001434647-26-000029
2026-04-2013:00 ETDEF 14AProxy statementPeriod 2026-06-040001434647-26-000025
2026-03-1611:31 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001434647-26-000015
2026-03-0920:23 ET10-KAnnual reportPeriod 2025-12-310001434647-26-000011
2026-03-0920:06 ET8-K2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001434647-26-000009
2025-12-1721:15 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001434647-25-000018

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 9, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1434647
Tickers
ZVRA
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
KEMPHARM, INC (to 2023-02-24); KEMPHARM INC (to 2011-06-30)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. Listed shows no prices and gives no investment advice.